Abbott Laboratories
ABT
$135.39
-$0.625-0.46%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.50B | 13.40B | 5.77B | 5.56B | 5.63B |
| Total Depreciation and Amortization | 3.17B | 3.22B | 3.22B | 3.25B | 3.24B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.14B | 1.16B | 802.00M | 802.00M | 793.00M |
| Change in Net Operating Assets | -8.86B | -9.22B | -1.07B | -1.71B | -2.52B |
| Cash from Operations | 8.95B | 8.56B | 8.73B | 7.90B | 7.14B |
| Capital Expenditure | -2.29B | -2.21B | -2.24B | -2.25B | -2.22B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 0.00 | -51.00M | -877.00M |
| Divestitures | 1.00M | 1.00M | 1.00M | 1.00M | 40.00M |
| Other Investing Activities | -91.00M | -132.00M | -55.00M | -40.00M | -39.00M |
| Cash from Investing | -2.38B | -2.34B | -2.30B | -2.34B | -3.10B |
| Total Debt Issued | 224.00M | 223.00M | 244.00M | 243.00M | 23.00M |
| Total Debt Repaid | -1.67B | -760.00M | -1.11B | -2.66B | -2.58B |
| Issuance of Common Stock | 417.00M | 264.00M | 273.00M | 237.00M | 239.00M |
| Repurchase of Common Stock | -1.35B | -1.30B | -1.24B | -490.00M | -913.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -3.91B | -3.84B | -3.77B | -3.69B | -3.62B |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -6.28B | -5.40B | -5.60B | -6.36B | -6.86B |
| Foreign Exchange rate Adjustments | -36.00M | -96.00M | 12.00M | -53.00M | -67.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 248.00M | 720.00M | 849.00M | -848.00M | -2.88B |